1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > The Human Microbiome: Biomedical Implications and Birth of a Market - Overview, CHI Insight Pharma Reports

Published in October, 2014, is Insight Pharma Reports’ The Human Microbiome: Biomedical Implications and Birth of a Market. This report covers the evolution of microbiome research and its growth in the commercial market. Specific areas of study include microbial ecology, systems biology, diet, diagnostics, contributions in health and disease, and infectious disease.

Microbiota have become a center for discussion and investigation after research has unraveled the symbiotic relationship between humans and their microbial counterparts, and the impact of the delicate balance of specific microbiota on various diseases. Such diseases include diabetes, Chronic Obstructive Pulmonary Disease (COPD), and Irritable Bowel Diseases (IBD). Understanding how microbiota act as communities, and thus is relation to disease, has been the topic of choice, known as microbial ecology, for several researchers. It has been demonstrated that when in equilibrium with their environment, microbiota gain benefits from the host, which enables them to provide useful benefits themselves. However, when this balance is disrupted, the repercussions can have a negative impact on human health. For example, the use of antibiotics can lead to vaginal yeast infections in women. This is because antibiotics kill not only the build-up of the infectious bacteria, but also all the other bacteria around it that keeps the control of yeast in check. Destroying these bacteria leads to the overgrowth of yeast and thus yeast infections.

In addition to antibiotics disrupting the microbiome environment, diet is another factor that can pose as a problem. A diet high in carbohydrates can also cause yeast build-up because yeast feed on sugar. Diet can also create an imbalance in the microbiome environment and jeopardize the symbiotic relationship between the microbiota and the host. A simple difference between consuming plant fats vs. animals fats has been demonstrated to have an effect on the abundance of certain types of bacteria in the gut over others, suggesting that these bacteria may be linked to weight loss and/or gain. In fact, researchers concluded there was a link between people who had animal-based dietary fats, bile acids, and irritable bowel diseases. Due to these findings, researchers are further investigating the relation between microbiota and the impact on various immune pathways, and the influence on obesity and diabetes.
In addition to covering several aspects of the microbiome, the report also includes the impact of this rising field on commercial aspects and product development.

Companies covered in this space include:

4D Pharma
ActoGenixAOBiome
AvidBiotics
CIPAC Limited
Enterome Bioscience
Human Longevity
Metabiomics
Microbiome Therapeutics
Miomics
OmniBiome Therapeutics
OptiBiotix
Osel Inc
OxThera
PathoGenetix
Rebiotix
Ritter Pharmaceuticals
Second Genome
Seres Health
uBiome
UCB
UC San Francisco
Vedanta
ViThera Pharmaceuticals
Whole Biome

Final features of the report include:

In-depth analysis of market data
Exclusive interview transcripts with the following experts:
Peter DiLaura, President & CEO, Second Genome
Colleen Cutcliffe, CEO, Whole Biome
James Brown, PhD; Head, Computational Biology; Head, Microbiome Matrix Team; GlaxoSmithKline
Jack Gilbert, PhD., Environmental Microbiologist, Assoc. Prof., Department of Ecology & Evolution, Argonne National Laboratory
Glenn Tillotson, PhD, Senior Partner, Transcrip Partners, USA
Peter P. Lee, MD, Executive Chairman, Osel, Inc.
Gregory Kuehn, VP Business Development and Marketing, Metabiomics
Stephen Elms, CEO, Miomics Bio-Therapeutics
Sydney M. Finegold, M.D., Emeritus Professor of Medicine, and Emeritus Professor of Microbiology, Immunology, and Molecular Biology, UCLA School of Medicine; Staff Physician, Infectious Disease Section, VA Greater Los Angeles Healthcare System

Table Of Contents

The Human Microbiome: Biomedical Implications and Birth of a Market - Overview, CHI Insight Pharma Reports
Executive Summary
Background and evolution
Basic microbiome research
Commercial activity in the microbiome space
Trends and conclusions
CHAPTER 1: Introduction
Scope and organization of the report
CHAPTER 2: Background and Evolution of Human Microbiome RandD
Exhibit 2.1 Estimated numbers of species and genes found in various body sites
Exhibit 2.2 PubMed citations for the search term ‘human microbiome'
CHAPTER 3: Research on the Human Microbiome
Culture
Systems Biology
Microbial Ecology
Diet
Virome
Diagnostics
The microbiome in health and disease
Infectious disease
CHAPTER 4: Commercial Aspects of Microbiome Research and Development
Companies active in the microbiome space
Exhibit 4.1
4D Pharma
ActoGenix
Alma BioTherapeutics
AObiome
AvidBiotics
CIPAC Limited
Enterome Bioscience SA
Human Longevity, Inc.
Metabiomics Corp.
Microbiome Therapeutics
Miomics
OmniBiome Therapeutics
OptiBiotix
Osel Inc.
OxThera
PathoGenetix
Rebiotix
Ritter Pharmaceuticals
Second Genome
Seres Health
uBiome
Vedanta Biosciences
ViThera Pharmaceuticals
Whole Biome
Deal Activity
Exhibit 4.2
Actogenix and Merck
CIPAC Ltd. and University of Minnesota
Enterome Biosciences and Synthetic Biologics
Enterome Bioscience and Mayo Clinic
Metabonomics and Kindstar
Second Genome and Pfizer
Second Genome and Janssen Biotech
Seres Health and Mayo Clinic
UCB and Harvard University
University of California, San Francisco and Janssen Research and Development
Vedanta Biosciences and Janssen Research and Development
Whole Biome and Mayo Clinic
CHAPTER 5: Market Survey
Exhibit 5.1 Participants' subject matter category in microbiome RandD
Exhibit 5.2 Type of organization where respondent work
Exhibit 5.3 Further categorization of workplace
Exhibit 5.4 Position titles of respondents
Exhibit 5.5 Type of work currently performed by respondents
Exhibit 5.6 Type of work likely to be performed by respondents during the next year
Exhibit 5.7 Disease focus for respondents' current or impending work
Exhibit 5.8 Respondents' expectation of change in their organization's microbiome involvement during the next two years
Exhibit 5.9 Opinion regarding academic participation in developing new concepts for Rx and/or Dx
Exhibit 5.10 Level agreement with statement: Current methods are adequate for quantitative characterization of microbiomes for personalized medicine
Exhibit 5.11 Level agreement with statement: Sufficient information about the composition and function of human microbiomes has been gathered to justify translational RandD
Exhibit 5.12 My work on detecting dysbiosis uses the following techniques
Exhibit 5.13 Respondents' view on the potential of microbiome RandD to provide major contributions to healthcare
Exhibit 5.14 Agreement with: Recent microbiome findings will enable an important new generation of therapies for chronic diseases
Exhibit 5.15 Agreement with: Recent microbiome findings will enable an important new generation of measures to maintain good health
Exhibit 5.16 Agreement with: It is still early days for microbiome-based translational medicine and years of basic research are required to establish its potential
Exhibit 5.17 Agreement with: Sequencing technology will remain dominant over microarrays for most microbiome diagnostic applications (N=63)
Exhibit 5.18 Agreement with: Big pharma will become heavily involved in microbiome related RandD over the next decade
Exhibit 5.19 Agreement with: We can expect to see a flood of new rationally-designed and/or personalized prebiotics to emerge during the next decade
CHAPTER 6: Trends and Conclusions
Microbiome market potential
Microbial ecology and systems level views of the human microbiome
Big pharma's involvement with the human microbiome
Food industry involvement with the human microbiome
Regulatory considerations
Consistency of results in analyzing microbiomes
Future directions
CHAPTER 7: Interview Transcripts
Peter DiLaura, President and CEO, Second Genome
Colleen Cutcliffe, CEO, Whole Biome
James Brown, PhD; Head, Computational Biology; Head, Microbiome Matrix Team; GlaxoSmithKline
Jack Gilbert, PhD., Environmental Microbiologist, Assoc. Prof., Department of Ecology and Evolution, Argonne National Laboratory
Glenn Tillotson, PhD, Senior Partner, Transcrip Partners, USA
Peter P. Lee, MD, Executive Chairman, Osel, Inc.
Gregory Kuehn, VP Business Development and Marketing, Metabiomics
Stephen Elms, CEO, Miomics Bio-Therapeutics
Sydney M. Finegold, M.D., Emeritus Professor of Medicine, and Emeritus Professor of Microbiology, Immunology, and Molecular Biology, UCLA School of Medicine; Staff Physician, Infectious Disease Section, VA Greater Los Angeles Healthcare System
About Cambridge Healthtech Institute

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market and Blood Disease Statistics

  • December 2016
    8 pages
  • Therapy  

    Blood Disease  

View report >

Cardiovascular Disease Statistics in the US

  • December 2016
    171 pages
  • Cardiovascular ...  

    Therapy  

  • United States  

View report >

Pathology Statistics in the US and the UK

  • December 2016
    12 pages
  • Pathology  

    Digestive Syste...  

    Cancer  

  • United States  

    United Kingdom  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.